InflaRx N.V. (IFRX)

Market Cap	131.90M
Revenue (ttm)	187,930
Net Income (ttm)	-63.44M
Shares Out	58.88M
EPS (ttm)	-1.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	88,739
Open	2.080
Previous Close	2.130
Day's Range	2.080 - 2.288
52-Week Range	1.165 - 2.815
Beta	1.67
Analysts	Strong Buy
Price Target	8.00 (+257.14%)
Earnings Date	Nov 8, 2024

About IFRX

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflamma...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 2017
• Employees: 62
• Stock Exchange: NASDAQ
• Ticker Symbol: IFRX
• Website: https://www.inflarx.de

Financial Performance

Financial numbers in EUR

Analyst Forecast

According to one analyst, the rating for IFRX stock is "Strong Buy" and the 12-month stock price forecast is $8.0.

Price Target

$8.0

(257.14% upside)

Analyst Consensus: Strong Buy